Published in J Parkinsons Dis on January 01, 2013
Sex differences in Parkinson's disease. Front Neuroendocrinol (2014) 0.92
Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front Cell Neurosci (2015) 0.87
Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology (2015) 0.81
Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure. BMC Syst Biol (2016) 0.78
Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Biomolecules (2015) 0.77
Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease. Sci Rep (2015) 0.75
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies. Biomolecules (2015) 0.75
Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. Front Neurosci (2017) 0.75
The Synucleinopathies: Twenty Years On. J Parkinsons Dis (2017) 0.75
Melatonin and Other Tryptophan Metabolites Produced by Yeasts: Implications in Cardiovascular and Neurodegenerative Diseases. Front Microbiol (2016) 0.75
Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis (2017) 0.75
Mutations in the Parkinson's Disease-Associated PARK2 Gene Are Accompanied by Imbalance in Programmed Cell Death Systems. Acta Naturae (2016) 0.75
Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. Elife (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Mechanisms of mitophagy. Nat Rev Mol Cell Biol (2011) 10.66
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Epidemiology of Parkinson's disease. Lancet Neurol (2006) 8.13
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Parkinson's disease. Lancet (2009) 6.60
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol (2006) 5.40
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci (1989) 4.01
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex (2001) 3.67
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol (1999) 3.63
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain (2007) 3.62
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol (2012) 3.42
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol (2010) 2.69
Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci (2007) 2.66
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry (2005) 2.54
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol (2012) 2.20
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol (2003) 2.14
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci (2010) 2.10
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci (2000) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol (2003) 1.94
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
A novel α-synuclein missense mutation in Parkinson disease. Neurology (2013) 1.74
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
Young onset Parkinson's disease. Mov Disord (1987) 1.67
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Catecholamine regulation of the prefrontal cortex. J Psychopharmacol (1997) 1.59
Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain (1999) 1.54
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology (2012) 1.51
The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol (2003) 1.49
Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol (2006) 1.47
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) (1992) 1.41
Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord (2009) 1.38
Orthostatic hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry (2006) 1.29
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord (2008) 1.27
The neuropsychology of Parkinson's disease. Brain Cogn (1995) 1.25
Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain (2001) 1.22
Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol (2000) 1.22
The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord (2011) 1.20
MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology (2011) 1.19
Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One (2009) 1.19
A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology (1997) 1.15
Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord (2012) 1.14
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord (2004) 1.14
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci (2005) 16.18
A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol (2002) 15.31
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Inhibition and the right inferior frontal cortex. Trends Cogn Sci (2004) 9.78
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet (2008) 7.31
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science (2007) 6.75
Parkinson's disease. Lancet (2009) 6.60
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci (2003) 5.94
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci (2004) 5.55
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci (2008) 4.85
High impulsivity predicts the switch to compulsive cocaine-taking. Science (2008) 4.76
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev (2004) 4.38
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Cognition in schizophrenia: summary Nice Consultation Meeting 2012. Eur Neuropsychopharmacol (2013) 3.99
Impulsivity, compulsivity, and top-down cognitive control. Neuron (2011) 3.96
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2007) 3.93
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes (2008) 3.76
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol (2013) 3.70
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest (2008) 3.51
Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci (2002) 3.50
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Contrasting roles of basolateral amygdala and orbitofrontal cortex in impulsive choice. J Neurosci (2004) 3.48
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Equity in access to total joint replacement of the hip and knee in England: cross sectional study. BMJ (2010) 3.16
The effect of rural-to-urban migration on obesity and diabetes in India: a cross-sectional study. PLoS Med (2010) 3.16
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
90-day mortality after 409,096 total hip replacements for osteoarthritis, from the National Joint Registry for England and Wales: a retrospective analysis. Lancet (2013) 3.00
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev (2006) 2.96
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci (2007) 2.95
Abnormal brain structure implicated in stimulant drug addiction. Science (2012) 2.85
Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol (2013) 2.85
Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr (2010) 2.82
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol (2010) 2.75
Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning. Ann N Y Acad Sci (2003) 2.70
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control (2008) 2.68
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res (2008) 2.61
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2009) 2.60
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nat Neurosci (2004) 2.52
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Serotonin modulates behavioral reactions to unfairness. Science (2008) 2.49
Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. J Neurosci (2002) 2.49
Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol (2010) 2.48
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47